Initiation, Adherence, and Persistence to Guideline-Directed Medical Therapy After Heart Failure Hospitalization: Bridging the Gap Between Prescription and Sustained Use

Despite increased prescription of guideline-directed medical therapy (GDMT) at discharge, primary nonadherence rates remain high across β-blockers, RAS inhibitors, MRAs, and SGLT2 inhibitors.
Early initiation and persistent use of quadruple therapy in heart failure with reduced ejection fraction (HFrEF) patients correlates with improved left ventricular ejection fraction and reduced adverse events.
Real-world data reveal suboptimal dose titration and frequent discontinuations, highlighting the need for interventions beyond initial discharge prescriptions.
Frailty and other patient factors influence GDMT use, underscoring the necessity for personalized approaches to optimize therapy adherence and persistence.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Despite increased prescription of guideline-directed medical therapy (GDMT) at discharge, primary nonadherence rates remain high across β-blockers, RAS inhibitors, MRAs, and SGLT2 inhibitors.
Early initiation and persistent use of quadruple therapy in heart failure with reduced ejection fraction (HFrEF) patients correlates with improved left ventricular ejection fraction and reduced adverse events.
Real-world data reveal suboptimal dose titration and frequent discontinuations, highlighting the need for interventions beyond initial discharge prescriptions.
Frailty and other patient factors influence GDMT use, underscoring the necessity for personalized approaches to optimize therapy adherence and persistence.

Sign in free to continue reading